TFF2 and cancer: Multiple classes of compounds decrease expression of Sp TFs in cancer cells, and these include structurally diverse ROS inducers, non-steroidal anti-inflammatory drugs (NSAIDs), cannabinoids and other drugs including retinoids, α—tocopherol thiazolidinediones, bortezomib, flavonoids and structurally diverse natural products and synthetic analogs [4,150].